2019-10-07
Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer
Publication
Publication
Results from the Dutch Castration-resistant Prostate Cancer Registry
European Urology Oncology , Volume S2588-9311
Background: Cross resistance between androgen-receptor targeting therapies(ARTs) (abiraterone acetate plus prednisone [ABI + P] or enzalutamide [ENZ]) fortreatment of metastatic castration-resistant prostate cancer (mCRPC) may affectresponses to second ART (ART2). Objective: To establish treatment duration and prostate-specific antigen (PSA)response of ART2 in real-world mCRPC patients treated with or without otherlife-prolonging drugs (LPDs; ie, docetaxel, cabazitaxel, or radium-223) betweenART1 and ART2.
Design, setting, and participants: Castration-resistant prostate cancer patients,diagnosed between 2010 and 2016 were retrospectively registered in Castra-tion-resistant Prostate Cancer Registry (CAPRI). Patients treated with both ARTswere clustered into two subgroups: ART1 > ART2 or ART1 > LPD > ART2.
| Additional Metadata | |
|---|---|
| , | |
| doi.org/10.1016/j.euo.2019.09.005, hdl.handle.net/1765/135464 | |
| European Urology Oncology | |
| Organisation | Institute for Medical Technology Assessment (iMTA) |
|
Kuppen, M., Westgeest, H., van den Eertwegh, F., van Moorselaar, R. J. A., van Oort, I., Coenen, J., van den Bergh, A., Mehra, N., Somford, D., Bergman, A., J.G.A. ten Bokkel (Daan), L. Fossion (Laurent), Geenen, M. M., Hendriks, M., A.C.M. van de Luijtgaarden (Addy), Polee, M., N.I. Weijl (Nir), van de Wouw, A., de Wit, R., … Gerritsen, W. (2019). Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. European Urology Oncology, S2588-9311.https://doi.org/10.1016/j.euo.2019.09.005 |
|
